Enzymotec is pleased to announce the termination, with promising results, of a clinical trial utilizing its Sharp-PS™.
This trial, conducted under the supervision of Prof. Vaisman at the Sourasky Tel-Aviv Medical Center, was an open-label study in which thirty elderly subjects with memory complaints were treated with Enzymotec's Sharp-PS™ for 12 weeks. Subjects' cognitive performance was assessed using a computerized assessment battery. The results show that treatment with Sharp-PS™ improved memory and attention parameters.
This trial is one among several trials conducted by Enzymotec in order to support the clinical efficacy of the company's products.
Enzymotec is an Israeli company, a developer and manufacturer of innovative biofunctional ingredients for clinical nutrition, dietary supplements, functional foods and infant formula.
The company develops and produces novel, lipid based ingredients including: CardiaBeat™ offering a broad health effect to reduce CVD risks, Sharp-PS™ and Sharp-PS™ GOLD for improving cognitive performance, and InFat™ for balanced nutrition for babies and toddlers.